Updated Pew Pipeline analysis of both traditional and non-traditional antimicrobial agents in development

Dear All:

To start the new year, I’ve learned that Pew has updated their pipeline analysis. First released in Feb 2014, it has been steadily updated ever since. This newest analysis has a data cut-off of Sep 2017 and covers both traditional antibiotics as well as non-traditional products. All the links you need are just below my signature, but let me point out a few highlights:

  • Separate commentaries are provided on the state of the traditional and non-traditional pipeline.
  • An excellent infographic is provided. Here’s a little piece of it. Combined with the idea that at most 1 in 5 of these products will reach registration, you have a very scary story indeed
  • As you know, WHO has also recently published a pipeline analysis. The two analyses are complementary and we have a joint blog from the organizations.
  • Pew’s analysis extends that of WHO by covering non-traditional products such as vaccines, microbiome products, immune enhancers, and more. There are 32 of these underway right now. As these are challenging and high-risk products to develop, I am glad to see this level of effort.
  • If you are interested in doing your own analytics, note that the pipeline charts are interactive and can be sorted by development phase, drug class, pathogen coverage, and more. You can also download past versions of the pipeline tables.

Core message: We have a pipeline, but it remains VERY thin. Let’s all get busy and see what can be developed to address the problem of antibiotic resistance!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Pew’s Dec 2017 Traditional/Small Molecule Antibiotics Analyses

Pew’s Dec 2017 Nontraditional Products Analyses

Upcoming meetings of interest to the AMR community:


AI-based drug discovery: Chemical vs. drugs (Part 4)

Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the original report has a new paper about identification of a narrow-spectrum compound with activity vs. Acinetobacter baumannii. Here are the links you’ll

WHO-UNEP-FAO-OIE Youth Engagement Working Group on AMR: Apply now!

“Education is the most powerful weapon we can use to change the world…” — Nelson Mandela Dear All, Regular readers will know my interest in developing the ecosystem of people who will work to address AMR over time (e.g., this interview with the founder of the Future Leaders Against AMR, my strong support for the

Reports calling for Pull: US GAO, Global AMR R&D Hub

Dear All, Two important reports for your awareness this afternoon. First, the Global AMR R&D hub have responded to a request from the G7 Finance and Health Ministers to provide an update to their 2022 progress report in advance of upcoming G7 meetings. As background, recall that the Finance Ministers in 2021 (during the UK G7

High Watermark for Pull Incentives (and more): Reflections on an amazing week!

Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …

Scroll to Top